Lantheus (NASDAQ:LNTH) Releases Earnings Results, Beats Expectations By $0.25 EPS

Key Points

• Lantheus beat quarterly expectations: The company reported EPS of $1.55, exceeding the $1.30 consensus by $0.25, while revenue reached $388.18 million versus estimates of $363.23 million. Revenue rose 2.7% year over year, though EPS declined from $1.57 a year earlier.
• Shares edged lower after the results: Lantheus traded at $100.95, with a market capitalization of $6.57 billion and a price-to-earnings ratio of 24.38. The stock remains near its one-year high of $111.86.
• Analyst sentiment is mixed: Five analysts rate the stock a Buy and nine rate it a Hold, producing an overall “Hold” consensus and an average price target of $108.11. Institutional investors own 99.06% of the company’s shares.

Lantheus (NASDAQ:LNTH - Get Free Report) issued its earnings results on Thursday. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25, FiscalAI reports. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million during the quarter, compared to the consensus estimate of $363.23 million. During the same period last year, the business posted $1.57 EPS. Lantheus's revenue was up 2.7% on a year-over-year basis.

Lantheus Stock Performance

Lantheus stock traded down $0.12 during trading hours on Friday, hitting $100.95. The company had a trading volume of 2,079,590 shares, compared to its average volume of 1,643,055. The firm has a 50-day moving average of $104.09 and a 200 day moving average of $87.98. The company has a debt-to-equity ratio of 0.43, a current ratio of 3.06 and a quick ratio of 2.64. The firm has a market cap of $6.57 billion, a PE ratio of 24.38 and a beta of -0.03. Lantheus has a one year low of $49.67 and a one year high of $111.86.

Hedge Funds Weigh In On Lantheus

A number of large investors have recently made changes to their positions in the company. Smartleaf Asset Management LLC grew its holdings in Lantheus by 63.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider's stock valued at $34,000 after buying an additional 197 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus in the second quarter valued at about $36,000. Parallel Advisors LLC increased its position in Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider's stock worth $36,000 after acquiring an additional 298 shares during the period. Los Angeles Capital Management LLC bought a new position in Lantheus during the fourth quarter worth about $39,000. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Lantheus in the 3rd quarter worth about $55,000. Institutional investors own 99.06% of the company's stock.

Analyst Ratings Changes

LNTH has been the topic of several research analyst reports. Citizens Jmp restated a "market outperform" rating and issued a $115.00 price objective on shares of Lantheus in a research note on Monday, June 29th. Citigroup reiterated an "outperform" rating on shares of Lantheus in a research note on Friday, May 8th. William Blair set a $102.50 target price on Lantheus in a report on Monday. Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $94.00 price target on shares of Lantheus in a research note on Thursday, May 7th. Five research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $108.11.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company's portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source